Ventyx Biosciences (VTYX)

• Market cap: $143M
• 1 day: 6.88%
• 5 days: -2.42%
• 1 month: -14.77%
• 3 months: -17.55%
• 6 months: -31.76%
• Year to date: -5.61%
• 1 year: -3.35%
• 5 years: -90.39%
• 10 years: -90.39%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Employees: 75

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

39% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 31

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

2% more funds holding

Funds holding: 116 [Q2] → 118 (+2) [Q3]

9% more call options, than puts

Call options by funds: $314K | Put options by funds: $288K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

7.41% less ownership

Funds ownership: 83.1% [Q2] → 75.69% (-7.41%) [Q3]

14% less capital invested

Capital invested by funds: $135M [Q2] → $117M (-$18.7M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9 346% upside
• Avg. target: $9 346% upside
• High target: $9 346% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Oppenheimer Jeff Jones 23% 1-year accuracy 9 / 40 met price target

346% upside $9

Outperform Reiterated

8 Nov 2024